Federico Nasroulah

2.1k total citations · 1 hit paper
29 papers, 993 citations indexed

About

Federico Nasroulah is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Federico Nasroulah has authored 29 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Federico Nasroulah's work include Colorectal Cancer Treatments and Studies (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Federico Nasroulah is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Federico Nasroulah collaborates with scholars based in United States, Spain and Japan. Federico Nasroulah's co-authors include Josep Tabernero, Rocio García‐Carbonero, Takayuki Yoshino, Tudor–Eliade Ciuleanu, G. Bodoky, David C. Portnoy, Eric Van Cutsem, Radka Obermannová, Jana Prausová and Allen Lee Cohn and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Federico Nasroulah

28 papers receiving 980 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Federico Nasroulah

Since Specialization

Citations

This map shows the geographic impact of Federico Nasroulah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Nasroulah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Nasroulah more than expected).

Fields of papers citing papers by Federico Nasroulah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Nasroulah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Nasroulah. The network helps show where Federico Nasroulah may publish in the future.

Co-authorship network of co-authors of Federico Nasroulah

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Nasroulah. A scholar is included among the top collaborators of Federico Nasroulah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Nasroulah. Federico Nasroulah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 2025 ·Nature Medicine ·Matthew D. Galsky, Dean F. Bajorin, Yoshihiko Tomita, Dingwei Ye, Mads Agerbæk, Deborah Enting, Avivit Peer, Matthew I. Milowsky, Ko Kobayashi, Marc‐Oliver Grimm, Frank Stenner, Justin M. David, (unknown), Scott D. Chasalow, Federico Nasroulah, (unknown), Keziban Ünsal-Kaçmaz, Andrea Necchi	0
2	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial 2023 ·Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, (unknown), Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, (unknown), (unknown), Zhisong He, Begoña P. Valderrama, (unknown), (unknown), Daniela Purcea, Federico Nasroulah, Matt D. Galsky	9
3	Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score 2023 ·European Urology ·Matthew D. Galsky, Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, (unknown), Sandra Collette, Begoña P. Valderrama, Marc‐Oliver Grimm, Leonard J. Appleman, Gwénaëlle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind‐Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz	14
4	Extended follow-up results from the CheckMate 274 trial. 2023 ·Journal of Clinical Oncology ·Matt D. Galsky, (unknown), Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, Frank Stenner, Santanu Dutta, Federico Nasroulah, Joshua Zhang, (unknown), Dean F. Bajorin	13
5	Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial 2022 ·European Urology Oncology ·J. Alfred Witjes, Matthew D. Galsky, Jürgen E. Gschwend, Edward Broughton, Julia Braverman, Federico Nasroulah, (unknown), Xiaomei Ye, Ling Shi, Shien Guo, Melissa Hamilton, Dean F. Bajorin	11
6	PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA 2022 ·The Journal of Urology ·Matthew D. Galsky, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Mads Agerbæk, Gautam Jha, (unknown), Sandra Collette, Keziban Ünsal-Kaçmaz, Federico Nasroulah, Joshua Zhang, Dean F. Bajorin	4
7	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set 2018 ·ESMO Open ·Axel Grothey, Takayuki Yoshino, G. Bodoky, Tudor–Eliade Ciuleanu, Rocio García‐Carbonero, Pilar García‐Alfonso, Eric Van Cutsem, Kei Muro, Daniel S. Mytelka, Li Li, (unknown), Yanzhi Hsu, Andreas Sashegyi, David Ferry, Federico Nasroulah, Josep Tabernero	13
8	Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial 2017 ·European Journal of Cancer ·Takayuki Yoshino, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Tae Won Kim, Yanzhi Hsu, David Ferry, Federico Nasroulah, Josep Tabernero	17
9	Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts). 2017 ·Journal of Clinical Oncology ·Axel Grothey, Josep Tabernero, Daniel S. Mytelka, Li Li, Federico Nasroulah, Takayuki Yoshino	1
10	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study 2017 ·Annals of Oncology ·Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Jana Prausová, Kei Muro, Robert W. Siegel, Robert J. Konrad, Haojun Ouyang, Symantha Melemed, D. Ferry, Federico Nasroulah, Eric Van Cutsem	78
11	Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors 2016 ·Cancer Chemotherapy and Pharmacology ·Ding Wang, Fadi Braiteh, James J. Lee, Crystal S. Denlinger, Dale R. Shepard, Archana Chaudhary, Yong Lin, Ling Gao, (unknown), Federico Nasroulah, Patricia LoRusso	2
12	Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer 2016 ·Annals of Oncology ·Sara Lonardi, (unknown), Takayuki Yoshino, Radka Obermannová, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, T-E. Ciuleanu, Pilar García‐Alfonso, David C. Portnoy, Eric Van Cutsem, Kentaro Yamazaki, P. Clingan, Jonathan Polikoff, Ling Gao, Lifen Yang, Sanders Chang, D. Ferry, Federico Nasroulah, Josep Tabernero	1
13	Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI 2016 ·Annals of Oncology ·Tudor–Eliade Ciuleanu, G. Bodoky, Rocio García‐Carbonero, Pilar Alfonso, Eric Van Cutsem, Kei Muro, Daniel S. Mytelka, (unknown), D. Ferry, Andreas Sashegyi, Federico Nasroulah, Josep Tabernero	1
14	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression 2016 ·Annals of Oncology ·Radka Obermannová, Eric Van Cutsem, Takayuki Yoshino, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, Pilar Alfonso, David C. Portnoy, Allen Lee Cohn, Kentaro Yamazaki, P. Clingan, Sara Lonardi, Tae‐Woo Kim, Lifen Yang, Federico Nasroulah, Josep Tabernero	53
15	Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status 2015 ·Annals of Oncology ·Alberto Sobrero, Luciano Latini, C. Barone, (unknown), Maria Banzi, Federico Nasroulah, (unknown), Josep Tabernero	1
16	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study breakdown → 2015 ·The Lancet Oncology ·Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah	652
17	Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors. 2015 ·Journal of Clinical Oncology ·(unknown), Fadi S. Braiteh, James J. Lee, Crystal S. Denlinger, Dale R. Shepard, Archana Chaudhary, Yong Lin, Ling Gao, (unknown), Federico Nasroulah, Patricia LoRusso	4
18	O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine 2015 ·Annals of Oncology ·Rocio García‐Carbonero, Radka Obermannová, G. Bodoky, Jana Prausová, Tudor–Eliade Ciuleanu, Pilar Alfonso, David C. Portnoy, Allen Lee Cohn, Eric Van Cutsem, Kentaro Yamazaki, Salah‐Eddin Al‐Batran, P. Rougier, Astra M. Liepa, Lifen Yang, Y. Zhang, Federico Nasroulah, (unknown), Josep Tabernero	6
19	An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer 2014 ·The Oncologist ·Rocio García‐Carbonero, Fernando Rivera, Joan Maurel, Jean-Pierre M. Ayoub, Malcolm J. Moore, Andrés Cervantes, Timothy R. Asmis, Jonathan D. Schwartz, Federico Nasroulah, (unknown), Josep Tabernero	51
20	PD5-2-7: Hiperfractionated (HFRT) versus Standard Radiotherapy (SRT) in Locally Advanced (LA) NSCLC: a metaanalysis of randomized phase III trials 2007 ·Journal of Thoracic Oncology ·Federico Nasroulah, Juan Manuel O’Connor, Maximiliano Van Kooten, Carlos Tajer, Reinaldo Chacón	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact